DADC
ARQT icon

D.A. Davidson & Co’s Arcutis Biotherapeutics ARQT Stock Holding History

D.A. Davidson & Co’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,458
Closed -$647K – 1598
2026
Q1 		$647K Sell
27,458
-1,285
-4% -$32.8K ﹤0.01% 1071
2025
Q4 		$835K Buy
+28,743
New +$736K 0.01% 958

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

D.A. Davidson & Co's ARQT Position: Q2 2026 in Review

D.A. Davidson & Co sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 27,458 shares — an estimated $647K sold.

D.A. Davidson & Co first reported a position in ARQT in Q4 2025 and held it in 2 quarters. The position peaked at $835K in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • D.A. Davidson & Co reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • D.A. Davidson & Co sold 27,458 Arcutis Biotherapeutics shares in Q2 2026, an estimated $647K.
  • D.A. Davidson & Co first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • D.A. Davidson & Co's Arcutis Biotherapeutics position peaked at $835K in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.